Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy.

Abstract

Checkpoint inhibitor immunotherapy has recently been proven to be an attractive treatment option for a wide variety of malignancies. Nivolumab, an anti-programmed cell death protein-1 antibody, has been proven effective and safe in treating metastatic renal cell carcinoma (RCC) with a clear cell component. We report the case of a patient with high-grade clear cell RCC with rhabdoid features who has achieved a durable complete response with nivolumab therapy after multiple surgical interventions and progression on pazopanib. Genomic evaluation in this case was characterized in part by a PBRM1 variant, similar to the only other described case of RCC with rhabdoid features obtaining a complete response to nivolumab. This case supports the potential utility of checkpoint inhibitors in aggressive, rare subtypes of RCC where there are limited options for therapy.

• Authors: Emily Wynja, Benjamin Solomon, Jonathan Bleeker
• Journal: Journal of immunotherapy (Hagerstown, Md. : 1997) (J Immunother) Vol. 41 Issue 7 Pg. 340-342 (09 2018) ISSN: 1537-4513 [Electronic] United States
• PMID: 29965859 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• PDCD1 protein, human
• Programmed Cell Death 1 Receptor
• Nivolumab

Topics

• Antineoplastic Agents (therapeutic use)
• Carcinoma, Renal Cell (diagnosis, immunology, therapy)
• Humans
• Immunotherapy (methods)
• Kidney Neoplasms (diagnosis, immunology, therapy)
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Neoplasm Staging
• Nephrectomy
• Nivolumab (therapeutic use)
• Programmed Cell Death 1 Receptor (immunology, metabolism)
• Remission Induction
• Rhabdoid Tumor (diagnosis, immunology, therapy)
• Tomography, X-Ray Computed